Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).

Autor:	Rosenberg JE; Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY., Park SH; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Kozlov V; Novosibirsk Reg Clinical Onc Dispensary, Novosibirsk, Russia., Dao TV; Vietnam National Cancer Hospital, Hanoi, Vietnam., Castellano D; Hospital Universitario 12 de Octubre, Madrid, Spain., Li JR; Taichung Veterans General Hospital, Hung Kuang University, Taichung, Taiwan., Mukherjee SD; Juravinski Cancer Centre, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada., Howells K; AstraZeneca, Cambridge, United Kingdom., Dry H; AstraZeneca, Gaithersburg, MD., Lanasa MC; AstraZeneca, Gaithersburg, MD., Stewart R; AstraZeneca, Cambridge, United Kingdom., Bajorin DF; Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
Jazyk:	angličtina
Zdroj:	Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Jan 01; Vol. 41 (1), pp. 43-53. Date of Electronic Publication: 2022 Jun 23.
DOI:	10.1200/JCO.22.00205
Abstrakt:	Purpose: Homologous recombination repair gene mutations (HRRm) are common in urothelial carcinoma (UC), rendering tumor cells sensitive to poly (ADP-ribose) polymerase (PARP) inhibition. We assessed efficacy and safety of durvalumab (anti-programmed cell death ligand-1) plus olaparib (PARP inhibitor) in patients with metastatic UC (mUC). Methods: This randomized, multicenter, double-blind, phase II trial enrolled untreated, platinum-ineligible patients with mUC. Patients (N = 154) were randomly assigned 1:1 to receive durvalumab (1,500 mg intravenously once every 4 weeks) plus olaparib (300 mg orally, twice daily) or durvalumab plus placebo. The primary end point was progression-free survival (PFS) assessed by investigators per RECIST version 1.1. Secondary end points included overall survival in all patients and PFS in patients with HRRm. Results: Overall, median PFS was 4.2 months (95% CI, 3.6 to 5.6) for durvalumab plus olaparib and 3.5 months (95% CI, 1.9 to 5.1) for durvalumab plus placebo (hazard ratio [HR], 0.94; 95% CI, 0.64 to 1.39; log-rank P value, .789). Median overall survival was 10.2 months (95% CI, 7.0 to 13.9) and 10.7 months (95% CI, 7.2 to 17.3), respectively (HR, 1.07; 95% CI, 0.72 to 1.61). In the 20% of patients with HRRm, median PFS was 5.6 months (95% CI, 1.9 to 8.1) and 1.8 months (95% CI, 1.7 to 2.2), respectively (HR, 0.18; 95% CI, 0.06 to 0.47). Treatment-related grade 3 or 4 adverse events occurred in 18% and 9% of patients, respectively. Conclusion: Adding olaparib to durvalumab did not improve survival outcomes in an unselected mUC population. Efficacy outcomes with durvalumab were similar to those reported for other anti-programmed cell death-1/programmed cell death ligand-1 agents. However, the results of secondary analyses suggest a potential role for PARP inhibition in patients with UC harboring HRRm.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu